Fast Track designation for Curis' lymphoma therapy

Curis Inc. (NASDAQ:CRIS) said FDA granted Fast Track designation to fimepinostat (formerly CUDC-907) to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in a third-line setting.

The product is an oral dual phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitor...